Added By
Curators' Team
Item Year
2015
Year Added
2025
Location
New York, NY
Source
BBC
Added By
Added By
Item Year
Item Year
Year Added
Item Year
Source
Item Year
Location
Item Year
LIVE LOUD
Turing Pharmaceuticals' CEO, Martin Shkreli—formerly a hedge-fund manager and often referred to as "Pharma Bro"—acquired Daraprim (pyrimethamine), a medication used to treat toxoplasmosis, from Impax Laboratories in August for $55 million. Following the acquisition, he raised the drug's price by an astonishing 5000%.
Originally approved by the Food and Drug Administration in 1953, GlaxoSmithKline marketed Daraprim for approximately $1 per tablet. In 2010, CorePharma purchased GlaxoSmithKline, and in 2014, Impax Laboratories acquired Core and its affiliated companies for $700 million, subsequently selling Daraprim for $13.50 per pill.
Daraprim remained relatively obscure until Turing Pharmaceuticals secured exclusive distribution rights and dramatically increased the price from $13.50…
Added By
Added By
Item Year
Added By
Year Added
Added By
Location
Added By
Source
Added By
Added By
Curators' Team
Item Year
2015
Year Added
2025
Source
BBC
Location
New York, NY
Pharma Bro
Turing Pharmaceuticals' CEO, Martin Shkreli—formerly a hedge-fund manager and often referred to as "Pharma Bro"—acquired Daraprim (pyrimethamine), a medication used to treat toxoplasmosis, from Impax Laboratories in August for $55 million. Following the acquisition, he raised the drug's price by an astonishing 5000%.
Originally approved by the Food and Drug Administration in 1953, GlaxoSmithKline marketed Daraprim for approximately $1 per tablet. In 2010, CorePharma purchased GlaxoSmithKline, and in 2014, Impax Laboratories acquired Core and its affiliated companies for $700 million, subsequently selling Daraprim for $13.50 per pill.
Daraprim remained relatively obscure until Turing Pharmaceuticals secured exclusive distribution rights and dramatically increased the price from $13.50…
SOURCE
Item Year
YEAR ADDED
Item Year
ADDED BY
Item Year
_edited.png)
.png)
.png)
ADDED BY
Item Year
ADDED BY
Curators' Team
LOCATION
Item Year
ITEM YEAR
Item Year
ITEM YEAR
Item Year
YEAR ADDED
Item Year
SOURCE
Item Year
LOCATION
Item Year
LOCATION
New York, NY
SOURCE
BBC
YEAR ADDED
2025
ITEM YEAR
2015
Pharma Bro
Turing Pharmaceuticals' CEO, Martin Shkreli—formerly a hedge-fund manager and often referred to as "Pharma Bro"—acquired Daraprim (pyrimethamine), a medication used to treat toxoplasmosis, from Impax Laboratories in August for $55 million. Following the acquisition, he raised the drug's price by an astonishing 5000%.
Originally approved by the Food and Drug Administration in 1953, GlaxoSmithKline marketed Daraprim for approximately $1 per tablet. In 2010, CorePharma purchased GlaxoSmithKline, and in 2014, Impax Laboratories acquired Core and its affiliated companies for $700 million, subsequently selling Daraprim for $13.50 per pill.
Daraprim remained relatively obscure until Turing Pharmaceuticals secured exclusive distribution rights and dramatically increased the price from $13.50 to $750 per tablet. This…
ADDED BY
Item Year
